☰

Inbiose

Updating the operating model

Industry
Biotechnology
Public information as of
January 2026

A4BEE prepared this analysis from publicly available sources. It reflects our own reading of Inbiose's published strategy and is not endorsed by, or produced in cooperation with, Inbiose. Company website

Strategic priorities

Inbiose operates across 4 stated priorities, with the most concrete near-term plan anchored on 100% microbe-free quality.

Ensuring infant-grade purity standards through rigorous contamination controls and validated production processes for the most sensitive nutrition applications.

Targeting an ambitious 12-month cycle from glycan concept to industrial scale-up using advanced automation, robotics, and ML-driven strain optimization.

Executing multi-jurisdictional market access strategy through simultaneous FDA GRAS notifications and EFSA Novel Food approvals for HMO portfolio expansion.

Challenges we see

  • Operations Manufacturing

    Industrial Scale-Up Complexity

    Transitioning fermentation from lab-scale to 66MT industrial volumes introduces non-linear complexity including gradients in oxygen, temperature, and nutrients that fundamentally alter process dynamics.

    High risk of batch failure or reduced yield at industrial volumes, which carries significant financial cost given the cost-per-batch at 66MT scale.

  • Digital Integration

    Fragmented Data Infrastructure

    Reliance on bespoke "in-house applications" for lab informatics creates data silos where strain performance data cannot be easily mapped to industrial fermentation outcomes.

    Manual data chains and non-standardized reporting create "lost in translation" gaps during the data journey from sensor to dashboard.

  • Operations Manufacturing

    External Manufacturing Dependency

    Inbiose relies on external upscaling partners for 66MT production volumes, requiring coordination between the Ghent R&D hub and distributed industrial sites.

    Limited direct control over the OT environment creates friction in troubleshooting and real-time process optimization at partner facilities.

  • Compliance Regulatory

    Multi-Jurisdictional Regulatory Burden

    Producing ingredients for infant formula requires simultaneous FDA GRAS notifications and EFSA Novel Food approvals with massive documentation requirements including 5-batch consistency data.

    Any gaps in generating required regulatory documentation can result in millions of euros in lost revenue and competitive positioning.

  • Digital Security

    IP Security Vulnerability

    The 70,000+ proprietary strain library and 2,000+ enzyme collection represent Inbiose's core competitive advantage and must be protected across a distributed global value chain.

    Connecting Ghent R&D hub with global manufacturing sites creates a broad attack surface for industrial espionage without Zero Trust architecture or IEC 62443 compliance.

Opportunities, by urgency and business impact

Each bubble is one opportunity, numbered to match the list below. Further right means it bites sooner; higher means a bigger effect on the business. A bigger bubble means a bigger implementation effort.

Source: A4BEE analysis of public sources

  1. Lab-to-Industrial Data Disconnect

    Current bespoke IT tools create "data islands" where R&D strain performance data cannot inform industrial fermentation decisions, leading to costly "double working" between scales.

    Implement a unified Industrial Data Platform with Universal Connector technology to create a single, GxP-compliant data stream from lab bench to production floor.

  2. Predictive Process Modeling Gap

    No enterprise-wide Digital Twin platform exists to simulate 66MT bioreactor performance, forcing reliance on expensive wet-lab experiments and high-risk industrial batch trials.

    Deploy a Digital Twin simulation environment to predict industrial outcomes and optimize process parameters before committing to costly 66MT batches.

  3. Legacy Equipment Visibility

    Millions invested in existing lab automation equipment lack the connectivity needed for data-driven decision making, limiting ROI on infrastructure investments.

    Retrofit existing pilot-scale equipment with control board® and IoT gateways to enable remote monitoring and precise control without full equipment replacement.

  4. Manual Compliance Documentation

    Transitioning from "research-grade" to "GMP-grade" data is a significant hurdle, with semi-digital processes posing audit risks for FDA GRAS and EFSA submissions.

    Implement paperless compliance infrastructure with bioprocess Control platforms ensuring GAMP5/FDA audit-ready data integrity across all regulatory jurisdictions.

  5. OT Security for Distributed Production

    Connecting R&D systems with external 66MT manufacturing partners creates cybersecurity vulnerabilities that could expose proprietary strain data or sabotage production batches.

    Implement Zero Trust architecture and IEC 62443 compliant OT security to protect the GlycoActives® IP across the entire global value chain.

What we'd propose

  • Digital Lab

    Digital Twin for Fermentation Scale-Up

    A cloud-based simulation platform that models 66MT bioreactor dynamics, enabling virtual experimentation and process optimization before committing to industrial batches.

    • Unified data backbone

      Connect instruments and LIMS into a single data spine so QC and CDMO records are queryable across sites.

      DETAIL

    • Paperless workflows

      Move lab execution from paper to instrument-captured records with full audit trail.

      DETAIL

    • Continuous QC release

      Review-by-exception dashboards that flag only the records needing scientist attention.

      DETAIL

    • Shorter lead time from data capture to decision.
    • Records that audit on their own, not on inspection day.
    • Scale without adding the same headcount.

    We've done this before

    See how we do Digital Lab
  • Enterprise AI

    Unified Lab Data Platform

    An enterprise-grade Industrial Data Platform using Universal Connector technology to unify data streams from 30+ equipment types into a single GxP-compliant source of truth.

    • Ontology layer

      A shared semantic model so lab, process, and quality data describe the same things the same way.

      DETAIL

    • Predictive models

      Models trained on the historical data plane that flag deviations before they become scrap.

      DETAIL

    • Decision surfaces

      Single pane of glass that surfaces model output to the right role at the right moment.

      DETAIL

    • Shorter lead time from data capture to decision.
    • Records that audit on their own, not on inspection day.
    • Scale without adding the same headcount.

    We've done this before

    See how we do Enterprise AI
  • Digital CDMO

    Legacy Equipment Retrofitting Program

    A systematic modernization of existing pilot-scale equipment using control board® and IoT gateways to enable smart connectivity without full equipment replacement.

    • OT/IT convergence

      Pull sensor and controller data off the line into a shared data plane in real time.

      DETAIL

    • Batch intelligence

      Golden-batch comparison and deviation detection running on the same data plane.

      DETAIL

    • Production release flow

      Closed-loop between QA, MES, and ERP so batch record review and release follow the data, not the paperwork.

      DETAIL

    • Shorter lead time from data capture to decision.
    • Records that audit on their own, not on inspection day.
    • Scale without adding the same headcount.

    We've done this before

    See how we do Digital CDMO
  • Digital Lab

    Paperless Compliance Infrastructure

    A comprehensive Laboratory Execution System (LES) implementation ensuring GMP-grade data integrity and automated compliance documentation for multi-jurisdictional regulatory submissions.

    • Unified data backbone

      Connect instruments and LIMS into a single data spine so QC and CDMO records are queryable across sites.

      DETAIL

    • Paperless workflows

      Move lab execution from paper to instrument-captured records with full audit trail.

      DETAIL

    • Continuous QC release

      Review-by-exception dashboards that flag only the records needing scientist attention.

      DETAIL

    • Shorter lead time from data capture to decision.
    • Records that audit on their own, not on inspection day.
    • Scale without adding the same headcount.

    We've done this before

    See how we do Digital Lab
  • Digital CDMO

    Zero Trust OT Security Framework

    A comprehensive cybersecurity overhaul implementing Zero Trust principles and IEC 62443 standards to protect proprietary strain data across the distributed production network.

    • OT/IT convergence

      Pull sensor and controller data off the line into a shared data plane in real time.

      DETAIL

    • Batch intelligence

      Golden-batch comparison and deviation detection running on the same data plane.

      DETAIL

    • Production release flow

      Closed-loop between QA, MES, and ERP so batch record review and release follow the data, not the paperwork.

      DETAIL

    • Shorter lead time from data capture to decision.
    • Records that audit on their own, not on inspection day.
    • Scale without adding the same headcount.

    We've done this before

    See how we do Digital CDMO

Digital maturity: today and target

Scored out of 100 across six dimensions. The target is what Inbiose's own published ambition implies — not a perfect score.

Source: A4BEE analysis of public sources
Data Integration 35 → 85
Bespoke in-house applications create data silos; need unified Industrial Data Platform
Process Simulation 25 → 80
No Digital Twin capability; relying on wet-lab experiments for scale-up validation
Equipment Connectivity 40 → 90
Advanced lab automation exists but lacks smart connectivity to central systems
Regulatory Compliance 45 → 95
Semi-digital processes pose audit risks; need paperless GxP infrastructure
Cybersecurity Maturity 30 → 85
Distributed production network lacks Zero Trust architecture and IEC 62443 compliance
Predictive Analytics 30 → 75
ML used for strain screening but not for industrial process optimization

Check this yourself

Our Service Portal has free self-assessments and market comparisons. These are the ones that line up with what we've read above — no sales call required.

Think we've read this right?

Talk to us

Related reading

This is an independent analysis prepared by A4BEE from publicly available information as of January 2026. It reflects A4BEE's own interpretation and opinion, is not affiliated with, endorsed by, or verified with Inbiose, and may be incomplete or inaccurate. All company names and trademarks are the property of their respective owners. To request a correction or removal, contact [email protected].